Last reviewed · How we verify
Camrelizumab and Chemotherapy
Camrelizumab and Chemotherapy is a PD-1 inhibitor Small molecule drug developed by Yue He, MD. It is currently in Phase 3 development for Nasopharyngeal carcinoma in combination with chemotherapy, Hepatocellular carcinoma in combination with chemotherapy, Esophageal squamous cell carcinoma in combination with chemotherapy.
Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to restore anti-tumor T-cell activity, used in combination with chemotherapy to enhance cancer cell killing.
Camrelizumab is a PD-1 inhibitor that blocks immune checkpoint signaling to restore anti-tumor T-cell activity, used in combination with chemotherapy to enhance cancer cell killing. Used for Nasopharyngeal carcinoma in combination with chemotherapy, Hepatocellular carcinoma in combination with chemotherapy, Esophageal squamous cell carcinoma in combination with chemotherapy.
At a glance
| Generic name | Camrelizumab and Chemotherapy |
|---|---|
| Sponsor | Yue He, MD |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Camrelizumab binds to programmed death receptor-1 (PD-1) on T cells, preventing interaction with PD-L1/PD-L2 ligands on tumor cells and reversing immune exhaustion. This checkpoint blockade restores cytotoxic T-cell function. When combined with chemotherapy, the chemotherapy provides direct cytotoxic effects while camrelizumab amplifies the immune response, creating a synergistic anti-tumor effect.
Approved indications
- Nasopharyngeal carcinoma in combination with chemotherapy
- Hepatocellular carcinoma in combination with chemotherapy
- Esophageal squamous cell carcinoma in combination with chemotherapy
Common side effects
- Fatigue
- Nausea
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Decreased hemoglobin
- Decreased neutrophils
Key clinical trials
- Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer (PHASE2)
- Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy (PHASE2)
- Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response (PHASE3)
- Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION) (PHASE3)
- Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma (PHASE3)
- Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer (PHASE2)
- Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer (PHASE2)
- Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Camrelizumab and Chemotherapy CI brief — competitive landscape report
- Camrelizumab and Chemotherapy updates RSS · CI watch RSS
- Yue He, MD portfolio CI
Frequently asked questions about Camrelizumab and Chemotherapy
What is Camrelizumab and Chemotherapy?
How does Camrelizumab and Chemotherapy work?
What is Camrelizumab and Chemotherapy used for?
Who makes Camrelizumab and Chemotherapy?
What drug class is Camrelizumab and Chemotherapy in?
What development phase is Camrelizumab and Chemotherapy in?
What are the side effects of Camrelizumab and Chemotherapy?
What does Camrelizumab and Chemotherapy target?
Related
- Drug class: All PD-1 inhibitor drugs
- Target: All drugs targeting PD-1
- Manufacturer: Yue He, MD — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Nasopharyngeal carcinoma in combination with chemotherapy
- Indication: Drugs for Hepatocellular carcinoma in combination with chemotherapy
- Indication: Drugs for Esophageal squamous cell carcinoma in combination with chemotherapy